News

09.09.2025

cellvie, a company pioneering therapeutics based on mitochondria, today announced the closing of a $5 million funding round, with participation from both existing and new investors. The round was led by Taiho Ventures, with major contributions from Kizoo Technology Capital, an existing investor, and Beiersdorf Venture Capital.

News

03.09.2025

The developed platform brings mitochondria transplantation treatment for ischemia-reperfusion injury one step closer to patients. cellvie and CSEM joined forces to design a new automated solution to streamline and standardize the manufacturing process. The system is GMP-compliant and ready to transfer to a Contract Development and Manufacturing Organization (CDMO) for Phase I trials.

News

24.10.2024

cellvie AG is thrilled to announce that it has been awarded a grant under the highly competitive Swiss Innovation Project (SIP) scheme of Innosuisse. The funded project will further establish and advance the use of mitochondria as delivery vectors for gene therapy payloads, a novel approach that could open new frontiers in gene therapy.

News

29.05.2024

BEING EARLY - There is a growing body of evidence showing that mitochondria are not only the powerhouses of a cell, but that their transfer may also function in rescue of cells in distress. Still early times, start-ups are already working to bring mitochondria therapy to the patient. EBM spoke to Alexander Schueller, CEO of Switzerland-based cellvie, about a long and winding road.

News

10.05.2024

CELLVIE presents at the Rejuvenation Startup Summit 2024 in Berlin. Dr. Alexander Schueller, cellvie’s CEO and co-founder, was one of the distinguished speakers invited from longevity biotech start-ups. Dr. Alexander Schueller presented the potential of mitochondria as a new treatment modality, not only for ischemia-reperfusion injury but also for aging related degeneration.

News

14.11.2023

cellvie, a pioneer in leveraging the therapeutic potential of mitochondria, together with CSEM, was selected as recipient of an Innosuisse grant with a total project value of more than CHF 700,000. The project funded focuses on advancing cellvie's mitochondrial isolation process to enable the scalable, safe, and cost-effective manufacturing of its therapy.

News

28.06.2023

At cellvie, we are committed to building a team capable to bring about this novel treatment paradigm. We are therefore thrilled to announce the strengthening of our leadership team, as we accelerate the translation of our off-the-shelf mitochondria therapy towards the clinic.

News

06.02.2023

Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality. $5.5M financing led by Taiho Ventures LLC, with the participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company’s technology platform, strengthening the team, and advancing the mitochondria’s GMP manufacturing

News

03.02.2023

cellvie, the leader in Therapeutic Mitochondria Transplantation moves its headquarters to Zürich. The new location features office space, a kitchen and meeting area and, most importantly, more than 100 sqm. state-of-art laboratory. The new office is found in Technopark Zürich, which offers a vibrant setting with around 260 firms of various sizes and stages of development, which come from many different industries.